Outdated dogma? Busulfan, seizure prophylaxis, and stem cell allografting

American Journal of Hematology

Volumn 87, Issue 9, 2012, Pages 941-941

  Ruiz Argüelles, Guillermo J ^a   Gomez Almaguer, David ^b   Steensma, David P ^c  

^a CENTRO DE HEMATOLOGÍA Y MEDICINA INTERNA DE PUEBLA   (Mexico)

^b Hospital Universitario de Nuevo León   (Mexico)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; BUSULFAN; CYCLOPHOSPHAMIDE; ETIRACETAM; FLUDARABINE; PHENYTOIN;

ANTICONVULSANT THERAPY; BLOOD BRAIN BARRIER; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL PRACTICE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LETTER; NEUROTOXICITY; PRIORITY JOURNAL; SEIZURE; TONIC CLONIC SEIZURE;

ADMINISTRATION, ORAL; ANTICONVULSANTS; ANTINEOPLASTIC AGENTS, ALKYLATING; BUSULFAN; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; SEIZURES; TRANSPLANTATION CONDITIONING;

EID: 84865378519     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23270     Document Type: Letter

References (9)

1. Newman DH. Believing in treatments that don't work. The New York Times 2 April 2009. Available at: http://well.blogs.nytimes.com/2009/04/02/the-ideology-of-health-care/.
2. Vassal G, Deroussent A, Hartmann O, et al. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study.Cancer Res 1990; 50: 6203-6207.
3. Eberly AL, Anderson GD, Bubalo JS, McCune JS. Optimal prevention of seizures induced by high-dose busulfan. Pharmacotherapy 2008; 28: 1502-1510.
4. Soni S, Skeens M, Termuhlen AM, et al. Levetiracetam for busulfan-induced seizure prophylaxis in children undergoing hematopoietic stem cell transplantation. Pediatr Blood Cancer 2012; Epub Feb 29. doi: 10.1002/pbc.24126.
5. Marcus RE, Goldman JM. Convulsions due to high-dose busulphan. Lancet 1984; 2:1463.
6. Ruiz-Argüelles GJ, Tarín-Arzaga LC, González-Carrillo ML, et al. Therapeutic choices in patients with Ph1 (+) chronic myelogenous leukemia living in México in the tyrosine kinase inhibitors (TKI) era: Stem cell transplantation or TKI's? Bone Marrow Transplant 2008; 42: 23-28.
7. Yeh RF, Pawlikowski MA, Blough DK, et al. Accurate targeting of daily intravenous busulfan with 8-hour blood sampling in hospitalized adult hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 2012; 18: 265-272.
8. Hassan M, Oberg G, Bjorkholm M, et al. Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemother Pharmacol 1993; 33: 181-186.
9. Ruiz-Argüelles GJ, Gómez-Almaguer D. Breaking dogmata to help patients: Non-myeloablative hematopoietic stem cell transplantation. Expert Opin Biol Ther 2004; 4: 1693-1699.